Kelan Medicine
珂阑医药
Kelan Medicine (珂阑医药, Cholesgen (Shanghai) Co. Ltd.) is a Shanghai-based innovative drug developer focused on cholesterol metabolism, using its financing to push core pipelines into the clinic and expand its R&D team. Per 高榕创投's announcements, it closed an oversubscribed Series A of over 100 million RMB in June 2023, led by Gaorong Capital with participation from Dawu Ventures, Nanwan Baiao Venture Fund, the AstraZeneca CICC Medical Industry Fund, and Sanyi Innovation Investment ; in February 2025 it followed with an oversubscribed A+ round of over 100 million RMB led by SDIC Venture Capital, with existing backer AstraZeneca CICC adding more capital . Beyond the funding history, elsewhere's corpus doesn't carry deeper detail on its science or team.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
Kailan Pharma Closes Oversubscribed A+ Round of Over 100 Million RMB to Advance Cholesterol Metabolism Drug R&D
Striving to provide alternative treatment options for patients with metabolic diseases.
Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
Kailan Pharma Closes Oversubscribed Series A Financing of Over 100 Million RMB to Advance Innovative Drug Development in Cholesterol Metabolism
Gaorong Ventures led the round.
